In this Reuters video, Leah Bennett of Concurrent Asset Management explains how AI has the potential to reduce the cost of clinical trials significantly – boosting drugmakers’ revenues by an estimated 12%. The clip suggests that improved efficiencies could spur a wave of mergers and acquisitions within the biotech sector.
Sectors Up Close: AI ‘could improve drugmaker revenues by 12%’
August 04, 2025